DiaSorin S.p.A. (DSRLF)
| Previous Close | 107.40 |
| Open | 107.40 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 107.40 - 107.40 |
| 52 Week Range | 86.00 - 120.00 |
| Volume | |
| Avg. Volume | 1 |
| Market Cap | 5.731B |
| Beta (5Y Monthly) | 0.15 |
| PE Ratio (TTM) | 34.76 |
| EPS (TTM) | 3.09 |
| Earnings Date | May 10, 2024 |
| Forward Dividend & Yield | 1.25 (1.17%) |
| Ex-Dividend Date | May 20, 2024 |
| 1y Target Est | N/A |
- Reuters
Diasorin CEO acquitted in Italy over alleged insider trading
An Italian court on Tuesday acquitted the chief executive of Italian diagnostics group Diasorin over allegations of insider trading. A panel of three judges in Milan acquitted Carlo Rosa, along with Alessandro Venturi, President of Policlinico San Matteo hospital in the northern city of Pavia. Prosecutors had themselves requested that Rosa be acquitted, while they asked for Venturi to be sentenced to two years' imprisonment.
- Reuters
DiaSorin confirms 2023 guidance after Q1 results
Q1 revenue plunged 20.6% year-on-year to 289.6 million euros ($318.79 million), leading to a 40.6% shrink in net profit, which came in at 41.7 million euros, the company said in a note. Revenue from COVID-related business unit dropped 78.5% in the first quarter, in line with an expected 75% decrease year-on year. DiaSorin confirmed its 2023 guidance for the full year, which sees total revenue down 14% on a yearly basis.
